PKAα/β/γ cat (phospho Thr198) Polyclonal Antibody

PRKACA (protein kinase cAMP-activated catalytic subunit alpha) encodes one of the catalytic subunits of protein kinase A, which exists as a tetrameric holoenzyme with two regulatory subunits and two catalytic subunits, in its inactive form. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. cAMP-dependent phosphorylation of proteins by protein kinase A is important to many cellular processes, including differentiation, proliferation, and apoptosis. Constitutive activation of this gene caused either by somatic mutations, or genomic duplications of regions that include this gene, have been associated with hyperplasias and adenomas of the adrenal cortex and are linked to corticotropin-independent Cushing's syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. Tissue-specific isoforms that differ at the N-terminus have been described, and these isoforms may differ in the post-translational modifications that occur at the N-terminus of some isoforms.

PRKACA; PKACA; cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha; PRKACB; cAMP-dependent protein kinase catalytic subunit beta; PKA C-beta; PRKACG; cAMP-dependent protein kinase catalytic subunit gamma; PKA C-gamma

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000; Not yet tested in other applications.

PRKACA; PKACA; cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha; PRKACB; cAMP-dependent protein kinase catalytic subunit beta; PKA C-beta; PRKACG; cAMP-dependent protein kinase catalytic subunit gamma; PKA C-gamma